First-Line Pharmacologic Treatment for Insomnia in Adults
For sleep onset and sleep maintenance insomnia, use eszopiclone (2-3 mg) or zolpidem (10 mg) as first-line pharmacologic agents; for sleep onset insomnia alone, use zaleplon (10 mg) or ramelteon (8 mg); for sleep maintenance insomnia alone, use suvorexant (10-20 mg) or low-dose doxepin (3-6 mg). 1
Key Context: Pharmacotherapy is NOT First-Line Overall
Before discussing specific medications, it's critical to understand that cognitive-behavioral therapy for insomnia (CBT-I) should be the initial treatment for chronic insomnia 1, 2. Pharmacotherapy is reserved for when CBT-I is unavailable, ineffective, or as an adjunct in selected cases.
Evidence-Based Medication Selection by Insomnia Type
The 2017 American Academy of Sleep Medicine (AASM) guideline provides the most comprehensive framework for pharmacologic selection 1:
For Both Sleep Onset AND Sleep Maintenance Problems:
- Eszopiclone (2-3 mg) - BZD receptor agonist with weak recommendation
- Zolpidem (10 mg) - BZD receptor agonist with weak recommendation
- Temazepam (15 mg) - Benzodiazepine with weak recommendation
For Sleep Onset Insomnia Only:
- Zaleplon (10 mg) - Shortest-acting BZD receptor agonist
- Ramelteon (8 mg) - Melatonin receptor agonist, useful when avoiding controlled substances
- Triazolam (0.25 mg) - Short-acting benzodiazepine
For Sleep Maintenance Insomnia Only:
- Suvorexant (10-20 mg) - Orexin receptor antagonist
- Doxepin (3-6 mg) - Low-dose tricyclic antidepressant
Important Nuances in the Evidence
All AASM recommendations carry WEAK strength 1, reflecting low-to-very-low quality evidence due to small trial sizes, short duration, publication bias from industry funding, and heterogeneity. This doesn't mean the medications are ineffective—it means clinicians must use judgment based on individual patient factors.
The 2016 American College of Physicians guideline found only eszopiclone, zolpidem, and suvorexant had sufficient evidence for short-term efficacy, though effect sizes were small 3. This aligns with AASM recommendations but emphasizes the modest benefits.
Duration of Treatment
Limit benzodiazepines and BZD receptor agonists (eszopiclone, zolpidem, zaleplon) to ≤4 weeks 2, 4. Longer-term use may be appropriate in select cases after careful risk-benefit assessment, but this increases risks of dependence, tolerance, and adverse effects.
Orexin receptor antagonists (suvorexant, daridorexant) can be used for up to 3 months or longer in some cases 2.
Medications to AVOID
The AASM explicitly recommends AGAINST 1:
- Trazodone - Despite widespread off-label use, evidence shows harms outweigh benefits
- Diphenhydramine (Benadryl) - Anticholinergic effects, next-day sedation, especially problematic in older adults
- Melatonin (immediate-release) - Insufficient evidence for insomnia disorder
- Tiagabine - Harms outweigh benefits
- Valerian, tryptophan - Insufficient efficacy evidence
Critical Safety Considerations
All hypnotics carry FDA warnings about cognitive and behavioral changes, including complex sleep behaviors (sleep-driving, sleep-walking) and next-day driving impairment 3. The FDA mandates dose reductions in women and older adults for many agents due to altered pharmacokinetics.
Observational studies suggest associations between chronic hypnotic use and increased risks of dementia, fractures, and major injury 3, though causality is not established. This reinforces the importance of short-term use and attempting discontinuation.
Practical Algorithm for Selection
- Identify insomnia phenotype: Sleep onset vs. maintenance vs. both
- Consider patient factors:
- Age (avoid benzodiazepines in elderly; consider low-dose doxepin or ramelteon)
- Substance use history (avoid controlled substances if abuse risk)
- Comorbidities (hepatic/renal function affects dosing)
- Match medication to phenotype using recommendations above
- Start at lowest effective dose
- Set clear expectations: Short-term use (2-4 weeks), not nightly dosing if possible
- Reassess regularly and attempt discontinuation
Special Populations
In adults ≥55 years: Prolonged-release melatonin (2 mg) can be used for up to 3 months 2, addressing age-related melatonin decline with lower risk than traditional hypnotics.
Avoid antihistamines and long-acting benzodiazepines in older adults due to anticholinergic effects, fall risk, and cognitive impairment 2, 4.
Common Pitfalls
- Using trazodone as first-line - This is not evidence-based and explicitly not recommended 1
- Prescribing without addressing perpetuating factors - Medication alone rarely resolves chronic insomnia
- Continuing indefinitely without reassessment - Increases harm risk without proven long-term benefit
- Using diphenhydramine in elderly patients - High anticholinergic burden and fall risk